Recombinant erythropoietin (Prolong Pharmaceuticals/Zydus Cadila)
N/A
Report date: 2022/01/14 13:23:58
Base Information
Drug NameRecombinant erythropoietin (Prolong Pharmaceuticals/Zydus Cadila)
Drug Alias Name
Classification
Mechanisms of Action
Targets
Therapy Area/Indications
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/Territory
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesProlong Pharmaceuticals LlcZydus Cadila
China Registration ClassN/A
Develop Information
Active CompaniesZydus CadilaProlong Pharmaceuticals Llc
Inactive CompaniesN/A
Active Indications
Inactive Indications
Other Information
ATC CodeN/A
Related LinksN/A